2252 Stock Overview
Shanghai Microport Medbot (Group) Co., Ltd.
Shanghai MicroPort MedBot (Group) Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$29.85|
|52 Week High||HK$73.45|
|52 Week Low||HK$19.92|
|1 Month Change||-14.10%|
|3 Month Change||23.86%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-34.83%|
Recent News & Updates
We're Not Very Worried About Shanghai MicroPort MedBot (Group)'s (HKG:2252) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|2252||HK Medical Equipment||HK Market|
Return vs Industry: Insufficient data to determine how 2252 performed against the Hong Kong Medical Equipment industry.
Return vs Market: Insufficient data to determine how 2252 performed against the Hong Kong Market.
|2252 Average Weekly Movement||14.0%|
|Medical Equipment Industry Average Movement||8.0%|
|Market Average Movement||6.5%|
|10% most volatile stocks in HK Market||12.8%|
|10% least volatile stocks in HK Market||3.2%|
Stable Share Price: 2252 is more volatile than 90% of Hong Kong stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: 2252's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
Shanghai Microport Medbot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People’s Republic of China and Europe. It offers Toumai, a laparoscopic surgical robot for use in urologic, gynecologic, thoracic, and general surgeries; DFVision, a 3D electronic laparoscope, which is used in laparoscopic surgeries for abdominal, thoracic, and pelvic organs; Honghu, an orthopedic surgical robot for knee arthroplasty and hip arthroplasty; R-One, a vascular interventional surgical robot for coronary angioplasty; and iSR’obot, a Mona Lisa robotic transperineal prostate biopsy system.
Shanghai MicroPort MedBot (Group) Fundamentals Summary
|2252 fundamental statistics|
Is 2252 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|2252 income statement (TTM)|
|Cost of Revenue||CN¥1.23m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 26, 2022
|Earnings per share (EPS)||-0.61|
|Net Profit Margin||-27,112.60%|
How did 2252 perform over the long term?See historical performance and comparison
Is 2252 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2252?
Other financial metrics that can be useful for relative valuation.
|What is 2252's n/a Ratio?|
Price to Book Ratio vs Peers
How does 2252's PB Ratio compare to its peers?
|2252 PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
853 MicroPort Scientific
6699 Angelalign Technology
2185 Shanghai Bio-heart Biological Technology
1302 LifeTech Scientific
2252 Shanghai MicroPort MedBot (Group)
Price-To-Book vs Peers: 2252 is expensive based on its Price-To-Book Ratio (10.3x) compared to the peer average (7.1x).
Price to Earnings Ratio vs Industry
How does 2252's PE Ratio compare vs other companies in the HK Medical Equipment Industry?
Price-To-Book vs Industry: 2252 is expensive based on its Price-To-Book Ratio (10.3x) compared to the Hong Kong Medical Equipment industry average (1.5x)
Price to Book Ratio vs Fair Ratio
What is 2252's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||10.3x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate 2252's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 2252 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 2252's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 2252's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Shanghai MicroPort MedBot (Group) forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2252 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2252 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2252 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2252's revenue (129.6% per year) is forecast to grow faster than the Hong Kong market (10% per year).
High Growth Revenue: 2252's revenue (129.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2252 is forecast to be unprofitable in 3 years.
Discover growth companies
How has Shanghai MicroPort MedBot (Group) performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 2252 is currently unprofitable.
Growing Profit Margin: 2252 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2252's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 2252's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2252 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (35.4%).
Return on Equity
High ROE: 2252 has a negative Return on Equity (-24.45%), as it is currently unprofitable.
Discover strong past performing companies
How is Shanghai MicroPort MedBot (Group)'s financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 2252's short term assets (CN¥2.1B) exceed its short term liabilities (CN¥234.5M).
Long Term Liabilities: 2252's short term assets (CN¥2.1B) exceed its long term liabilities (CN¥167.3M).
Debt to Equity History and Analysis
Debt Level: 2252 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 2252's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2252 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 2252 has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 93.7% each year.
Discover healthy companies
What is Shanghai MicroPort MedBot (Group) current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2252's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2252's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2252's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2252's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 2252 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chao He (37 yo)
Dr. Chao He is President and Executive Director of Shanghai Microport Medbot (Group) Co., Ltd. since December 2020 and since October 18, 2017. Dr. He joined the Group in May 2015.Prior to joining our Grou...
CEO Compensation Analysis
Compensation vs Market: Chao's total compensation ($USD4.78M) is above average for companies of similar size in the Hong Kong market ($USD468.92K).
Compensation vs Earnings: Chao's compensation has increased whilst the company is unprofitable.
Experienced Management: 2252's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: 2252's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: 2252 only recently listed within the past 12 months.
Shanghai MicroPort MedBot (Group) Co., Ltd.'s employee growth, exchange listings and data sources
- Name: Shanghai MicroPort MedBot (Group) Co., Ltd.
- Ticker: 2252
- Exchange: SEHK
- Founded: 2014
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: HK$27.847b
- Shares outstanding: 958.59m
- Website: https://www.medbotsurgical.com
Number of Employees
- Shanghai MicroPort MedBot (Group) Co., Ltd.
- Building 1
- Room 101, Area B
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/18 00:00|
|End of Day Share Price||2022/08/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.